Teva Pharmaceutical Industries Ltd. today announced top-line results from an exploratory dose-ranging Phase 2 clinical trial, which could be a major breakthrough in the treatment of Huntigton’s Disease (HD).
This was a 52-week trial of pridopidine twice daily versus placebo. The study was directed at measuring improvement in motor function and the effect on Huntington Disease progression. The effect of Pridopidine was further evident in a sub-population of patients with early stage HD, an effect first observed at 26 weeks.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at [email protected].
Thank you.
“Slowing down the progression of this disease has proven to be impossible until now. These findings give us a reason to believe we may be finally making progress in slowing deterioration of disease, ” said Spyros Papapetropoulos, Teva’s VP Clinical Development, Neurodegenerative Diseases.
This was a 52-week, dose-ranging trial of Pridopidine twice daily versus placebo, in the treatment of Huntington disease (HD). The study was directed at measuring improvement in motor function and the effect on HD progression. An unusually high placebo effect, extending beyond that expected from previous studies, limited the ability to determine treatment effects on assessments of HD motor scores. Evidence of symptomatic impact, however, was seen in the early stage HD patient sub-population, with improvement in Total Motor Score (TMS) and dystonia observed at 26 and 52 weeks in this patient sub-set (stage 1 HD) at specific doses.
The discovery of Pridopidine’s previously unknown mode of action as a potent agonist of the Sigma 1 Receptor (S1R) resulted in a change in PRIDE-HD study design, from a 26-week study focused on symptoms, to a 52-week study focused on exploring pridopidine’s potential impact on disease progression, as measured by Total Functional Capacity (TFC).
“I am encouraged by these results, which provide us with clear insights into the approach to be taken in Phase III development”, said Michael Hayden, President of Teva Global R&D and Chief Scientific Officer. “My obvious hope is that this will provide the HD community with a medicine capable of slowing down the progression of this devastating disease.”
“These study results are very important for the HD community and for the continued development of pridopidine. Firstly, pridopidine’s safety profile has been confirmed and extended. Secondly, we now have a clearer idea of the dosages to study in Phase 3. Lastly, we have some of the most encouraging evidence to date about an intervention which may slow the inexorable functional decline of HD, ” said Karl Kieburtz, M.D., M.P.H., Director of the Clinical & Translational Science Institute at the University of Rochester Medical Center.
The results seen in this exploratory study will need to be confirmed in a Phase III program that will be developed in collaboration with relevant regulatory agencies.
Pridopidine is an investigational, oral small molecule being developed for the treatment of HD that exerts its effect as an agonist of S1R. S1R plays a key role in neuroprotection through increased production of brain-derived neurotrophic factor (BDNF). Levels of BDNF are decreased in HD and other neurodegenerative disorders including Parkinson’s disease, Alzheimer’s disease and ALS.
